Synchronous Renal Cell Carcinoma and Primary Ocular Malignant Melanoma: Case Report
Renal cell carcinoma (RCC) and malignant melanoma (MM) are ranked as the eighth and the fifth most frequent malignancies in the United States, respectively, and the incidence is increasing. Recent studies have shown an increased risk of second primary cancer in patients with RCC or MM, demonstrating a severe risk of RCC in patients with MM, and a severe risk of MM in patients with RCC. Ocular melanoma is a rare melanoma subtype and accounts for 3.7% of all melanoma cases. A potential symmetrical relationship between ocular MM and the development of kidney cancer may be explained by the common risk factors and mechanisms of these 2 malignancies. Chromosome-3 abnormalities have commonly been reported in patients with ocular melanoma and kidney cancers. While previous studies have shown an increased incidence of MM in patients with RCC and vice versa, subanalysis of demographic tumor factors has been unavailable due to the small number of patients who have developed both cancers.
1.Abern MR, Tsivian M, Coogan CL, Kaufman HL, Polascik TJ. Characteristics of patients diagnosed with both melanoma and renal cell cancer. Cancer Causes Control 2013;24:1925– 33. [CrossRef ]
2. McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer 2005;103:1000–7. [CrossRef ]
3. Crocetti E, Guzzinati S, Paci E, Falcini F, Zanetti R, Vercelli M, et al. The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries). Melanoma Res 2008;18:230–4. [CrossRef ]
4. Wu YH, Kim GH, Wagner JD, Hood AF, Chuang TY. The association between malignant melanoma and noncutaneous malignancies. Int J Dermatol 2006;45:529–34. [CrossRef ]
5. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 2001;145:981–5. [CrossRef ]
6. Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010;146:265–72. [CrossRef ]
7. Beisland C, Talleraas O, Bakke A, Norstein J. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int 2006;97:698–702.
8. Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ. Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol 2013;36:132–42. [CrossRef ]
9. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 1993;29:228–36. [CrossRef ]
10. Koga S, Tsuda S, Nishikido M, Matsuya F, Saito Y, Kanetake H. Renal cell carcinoma metastatic to the skin. Anticancer Res 2000;20:1939–40.
11. Ather MH, Masood N, Siddiqui T. Current management of advanced and metastatic renal cell carcinoma. Urol J 2010;7:1–9.
12. Weiss L, Harlos JP, Torhorst J, Gunthard B, Hartveit F, Svendsen E, et al. Metastatic patterns of renal carcinoma: an analysis of 687 necropsies. J Cancer Res Clin Oncol 1988;114:605–12.
13. Shields JA, Shields CL. Introduction to melanocytic tumors of the uvea. Intraocular Tumors: A Text and Atlas. Philadelphia, Pa: Saunders; 1992. p. 45–59.
14. Ritchie AW, Chisholm GD. The natural history of renal carcinoma. Semin Oncol 1983;10:390¬–400.
15. Scélo G, Boffetta P, Autier P, Hemminki K, Pukkala E, Olsen JH, et al. Associations between ocular melanoma and other primary cancers: an international population-based study. Int J Cancer 2007;120:152–9. [CrossRef ]
16. Masood J, Lane T, Koye B, Vandal MT, Barua JM, Hill JT. Renal cell carcinoma: incidental detection during routine ultrasonography in men presenting with lower urinary tract symptoms. BJU Int 2001;88:671–4. [CrossRef ]
17. Baggetto LG, Gambrelle J, Dayan G, Labialle S, Barakat S, Michaud M, et al. Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects. Cancer Treat Rev 2005;31:361–79. [CrossRef ]